NCT00019890View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Study Completion Date

March 31, 2007

Conditions

Stage IV MelanomaStage III MelanomaRecurrent Melanoma

Interventions

DRUG

dendritic cell-gp100-MART-1 antigen vaccine

DRUG

sargramostim

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH